Jennypher Mudunuru, MS, PhD, GSK

Jennypher Mudunuru, Ph.D., is an accomplished Modeling Scientist specializing in Drug Metabolism and Pharmacokinetics (DMPK) at GlaxoSmithKline (GSK). With a robust foundation in pharmacokinetics and expertise in DMPK and Absorption, Distribution, Metabolism, Excretion (ADME), Dr. Mudunuru is proficient in Physiologically Based Pharmacokinetic (PBPK) modeling and simulations. She obtained her Master’s in Pharmaceutics and her Ph.D. in Pharmaceutics and Drug Design from Long Island University, where her doctoral research focused on Drug Metabolism and Pharmacokinetic assessment for Investigational New Drug (IND) enabling studies at an oncology-focused small molecule firm.

During her doctoral studies, Dr. Mudunuru designed and executed safety and efficacy studies in preclinical species, conducted in vitro metabolism evaluations, and demonstrated expertise in cancer cell culture and tumor xenograft models for pharmacokinetic (PK) and pharmacodynamic (PD) endpoints. In her current capacity at GSK, she is the lead PBPK Modeler across multiple initiatives, contributing to Model Informed Drug Development with an emphasis on drug-drug interactions (DDIs), modified pharmacokinetics due to disease states, and supporting clinical study designs primarily in oncology and immunology for both small and large molecules.

Dr. Mudunuru has been instrumental as the lead modeler on pre-candidate selection projects, supporting milestones related to First-Time in Human dosing for candidate selection. She has steered numerous projects, displaying her proficiency in managing drug-drug interactions and special population studies. Her current focus revolves around constructing and employing special population models to achieve more accurate estimations of pharmacokinetic profiles and drug-drug interactions in diverse molecular formats.

Dr. Mudunuru has made significant contributions to multiple regulatory submissions concerning First-Time in Human studies and drug-drug interactions across Phase 1, Phase 2, Phase 3, and post-market approval inquiries. Her research achievements have been showcased at esteemed conferences, including the IQ Consortium, ISSX, AAPS, Gordon Research Conference, Simcyp Annual Consortium, and AACR. She has garnered several high-performance accolades and individual awards at GSK, as well as external recognition for her impactful work and extensive contributions to the field.